If you have been into ATOS SINCE THE initial Private Placement , and through the $5 IPO in 2012 , you know that "we aint seen nuttin yet".
In '12/13 this co rocketed up to $13, then when quesitons came in from the FDA about certain claims that were "supposedly made" the co took it's Foresite product off the market voluntarily. Then for at least one year they made due with with the preliminary FDA approval process, after which they got another round of questions, and finally were turned down for their Foresite product, one of 5 products. They did however have approval for their next generation product Fullcyte, and although it is not as accurate as the Forecyte product, it is far and away more accurate than the next level of competition, which by the way, has a valuation in the 100's of millions (i recall $300 mln) . And by the way , Forcyte recently got it's European equivalent of FDA approval with a CE Mark in Europe.
So now you have the enviable position of a launch over seas. Their secont product Fullcyte just launched here in the States , and the pharmacogenetics also just recently launched.
Did i mention there are two more applications? You even have one application that addresses very early stage CA in the breast ducts .
Be that as it may, the reason i have remained in the opportunity since 2011 and stockpiled is for the perseverance , resiliance and genius of Steven Quay. He is technical genius , a marketing genius, and quant strategist.
This isnt going to stop at $5.5 as Zach's suggests , and now commercialized we will driven by accelerating revenue growth.
By the way , where did their huge patent portfolio come from? They purchase $1.4 billion in Paatent IP for a song, part from Roche and part from Sanofi Aventis, (if it wasnt Sanofi , it was a simlilar name recognized Pharma). They also have acquired Susan Day's IP!
And there are a lot more reasons than this, but this touches on some of the why's that convinced me to BE HERE.
News 
Market Data 
Discover 
